Data Insights
No Filter Selected
No Filter Selected
No Filter Selected
No Filter Selected
Azenosertib by Zentalis Pharmaceuticals for Peritoneal Cancer: Likelihood of Approval
Azenosertib is under clinical development by Zentalis Pharmaceuticals and currently in Phase II for Peritoneal Cancer. According to GlobalData, Phase...
Azenosertib by Zentalis Pharmaceuticals for Fallopian Tube Cancer: Likelihood of Approval
Azenosertib is under clinical development by Zentalis Pharmaceuticals and currently in Phase II for Fallopian Tube Cancer. According to GlobalData,...
Azenosertib by Zentalis Pharmaceuticals for Ovarian Cancer: Likelihood of Approval
Azenosertib is under clinical development by Zentalis Pharmaceuticals and currently in Phase II for Ovarian Cancer. According to GlobalData, Phase...
Risk adjusted net present value: What is the current valuation of Zentalis Pharmaceuticals's Azenosertib?
Azenosertib is a small molecule commercialized by Zentalis Pharmaceuticals, with a leading Phase II program in Osteosarcoma. According to Globaldata,...